MRC funds £20m Cambridge hub to replace animal models with AI and human organoids
A new research initiative at the Cambridge Biomedical Campus aims to increase clinical trial success rates by using stem cell-derived 'mini-organs'.
The Medical Research Council (MRC) has launched a £20 million research hub at the Cambridge Biomedical Campus to overhaul how new medicines are developed. The initiative aims to replace traditional preclinical testing with a combination of artificial intelligence, bioengineering, and advanced human lab models.
Led by Professor Matthias Zilbauer and Professor Bertie Göttgens of the Cambridge Stem Cell Institute (CSCI), the hub focuses on the use of 'organoids'—miniature organs grown from human stem cells—and AI-powered analysis to study diseases. The project is a collaborative effort involving several high-profile partners, including Cambridge University Hospitals (CUH), the Wellcome Sanger Institute, the MRC-Laboratory of Molecular Biology (MRC-LMB), and Royal Papworth Hospital.
The failure of animal models
For decades, the pharmaceutical industry has relied heavily on animal models to predict how a drug will behave in the human body. However, these models frequently fail to mirror human biological responses, leading to high attrition rates once a drug reaches clinical trials. By shifting the focus to human-based predictive models, researchers hope to identify failures earlier in the pipeline.
Chris McDonald, the UK Minister for Science, Research and Innovation, noted that too many medicines that appear effective in animals ultimately fail in people. He stated that the Preclinical Translational Models Hub will enable scientists to test treatments on human tissue grown from patients' own cells to determine more accurately what will genuinely work.
Implications for drug development
Located at the Jeffrey Cheah Biomedical Centre, the hub is strategically positioned near major industry players such as GSK and AstraZeneca. This proximity allows for a tighter integration between academic research and commercial drug development. Professor Matthias Zilbauer, a hub co-lead, explained that by capturing the specific characteristics of individual patients, these human models allow for more accurate disease study and treatment testing before they ever reach a clinic.
Beyond improving the success rate of trials, the shift toward AI and organoids is expected to lower the overall cost and time required to bring new therapies to market. Furthermore, the initiative represents a significant step toward the UK's goal of reducing and eventually ending the reliance on animal testing in medical development.
Future outlook
As the hub begins its operations, the industry will be watching to see how effectively these AI-driven human models can be scaled to replace standard regulatory animal tests. While the integration of bioengineering and stem cell research offers a promising path forward, the transition will require rigorous validation to ensure that organoids can fully replicate the complexity of a living human system.